Jana Debarshi, Mandal Syamsundar, Mukhopadhyay Madhumita, Mitra Debabrata, Mukhopadhyay Sunit K, Sarkar Diptendra Kumar
Breast Cancer Research Unit, Breast Service, Institute of Post Graduate Medical Education and Research (IPGME and R) and Seth Sukhlal Karnani Memorial Hospital (SSKM), Kolkata, India.
Asian Pac J Cancer Prev. 2012;13(8):3851-5. doi: 10.7314/apjcp.2012.13.8.3851.
The worldwide incidence of breast cancer has increased rapidly in recent years. The scenario of Eastern India is also showing the same trend. It is necessary to study the utility of HER-2/neu as a prognostic factor in breast cancer survival. However, there have not been detailed studies in this respect with the breast cancer patients of Eastern India. Thus this study was conducted.
In this hospital-based study 86 breast cancer patients attending a breast clinic of a reputed institute of Eastern India and having invasive ductal carcinomas were observed for a period of 5 years after surgery. Associations between 5 years observed survival and status of ER, PR and HER-2/neu of the patients were critically evaluated.
There was statistically significant association between survival pattern for 5 years and the HER-2/neu status (p=0.00001). Better survival was observed for the patients with HER-2/neu negative tumors 67(100%) compared to HER-2/neu positive tumors 7(36.8%).
There is strong interaction between survival and HER-2/neu expression of breast cancer patients. Thus the patients with HER-2/neu positive tumors need to be treated aggressively.
近年来，全球乳腺癌发病率迅速上升。印度东部地区的情况也呈现出相同趋势。有必要研究HER-2/neu作为乳腺癌生存预后因素的效用。然而，对于印度东部的乳腺癌患者，尚未有这方面的详细研究。因此开展了本研究。
在这项基于医院的研究中，对86例在印度东部一家知名机构的乳腺诊所就诊且患有浸润性导管癌的乳腺癌患者进行了术后5年的观察。对患者5年观察生存率与雌激素受体（ER）、孕激素受体（PR）及HER-2/neu状态之间的关联进行了严格评估。
5年生存模式与HER-2/neu状态之间存在统计学显著关联（p = 0.00001）。与HER-2/neu阳性肿瘤患者7例（36.8%）相比，HER-2/neu阴性肿瘤患者67例（100%）的生存率更高。
乳腺癌患者的生存与HER-2/neu表达之间存在强烈相互作用。因此，HER-2/neu阳性肿瘤患者需要积极治疗。
